Evidence map›Paper›PMID 41190085›Full record

ReviewFrontiers in surgery2025

KIAA1429 in non-small cell lung cancer: bridging m6A epigenetics to therapeutic innovation.

Hui Liu, Ke Shi, Liang Liu, Bo-Hua You, Tao Liu, Xiao-Fei Ren, Qiang Guo, Dan Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hui Liu *Department of Ultrasound Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Ke Shi *Department of Thoracic Surgery, Beilun District People's Hospital of Ningbo, Ningbo, China.
Liang Liu *Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Bo-Hua YouDepartment of Thoracic Surgery, The People's Hospital of Honghu, Jingzhou, China.
Tao LiuDepartment of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Xiao-Fei RenDepartment of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Qiang GuoDepartment of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Dan LiDepartment of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a pivotal component of the m6A methyltransferase complex, KIAA1429 plays a critical regulatory role in the pathogenesis of non-small cell lung cancer (NSCLC), driving tumorigenesis, metastasis, and therapeutic resistance through epigenetic mechanisms. Clinically, KIAA1429 overexpression correlates with aggressive disease progression and poor patient prognosis to conventional therapies. This review comprehensively examines the dysregulated expression patterns and functions of KIAA1429 in NSCLC, elucidating its m6A-dependent modulation of key downstream effectors (Such as the HOXA1, DAPK3, and BTG2) that orchestrate malignant transformation. We highlight the emerging potential of KIAA1429 as a novel molecular target for precision therapy in NSCLC.

Indexed as

gefitinib resistanceKIAA1429m6A modificationmolecular targetnon-small cell lung cancer

Identifiers

PMID41190085
PMCPMC12580200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.